Citation:Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al 2009

From Cancer Guidelines Wiki

Citation


Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009 Mar;14(3):253-63 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19221167.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al 2009What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al 2009 2What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al 2009 3What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Scagliotti_G,_Hanna_N,_Fossella_F,_Sugarman_K,_Blatter_J,_Peterson_P,_et_al_2009&oldid=21651"